<DOC>
	<DOCNO>NCT01699932</DOCNO>
	<brief_summary>Primary Objective : -To demonstrate efficacy fix combination glimepiride + metformin term HbA1c reduction , 24-week treatment period patient inadequately control type 2 diabetes mellitus . Secondary Objective : To assess effect fix combination glimepiride metformin week 24 : - Percentage patient reach HbA1c &lt; 7 % - Percentage patient reach HbA1c &lt; 6.5 % . - Fasting Plasma Glucose ( FPG ) - Safety tolerability</brief_summary>
	<brief_title>Efficacy Safety Fixed Dose Combination Glimepiride+Metformin Type 2 Diabetic Patients Inadequately Controlled</brief_title>
	<detailed_description>The study duration patient approximately 27 week 3 period : 2-week screening period follow 24-week treatment period 3 day follow-up period last call phone visit .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criterion : Patients type 2 diabetes mellitus inadequately control despite treatment sulfonylurea ( SU ) alone metformin alone free combination SU metformin prior study entry . Signed informed consent , obtain prior study procedure Exclusion criterion : Age &lt; legal age adulthood HbA1c &lt; 7 % ≥ 11 % BMI &gt; 35 kg/m2 Treatment stable dose maximally tolerate SU alone metformin alone free combination SU metformin le 12 week prior screen visit . Patients receive antidiabetic drug SU metformin within 12 week prior screen visit . Diabetes type 2 diabetes ( e.g . type 1 diabetes , diabetes secondary pancreatic disorder , drug chemical agent intake… ) The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>